{"created":"2023-05-15T16:33:25.841668+00:00","id":5660,"links":{},"metadata":{"_buckets":{"deposit":"4a3d3ad7-3d3b-4e15-af4b-f4414774c3e9"},"_deposit":{"created_by":2,"id":"5660","owners":[2],"pid":{"revision_id":0,"type":"depid","value":"5660"},"status":"published"},"_oai":{"id":"oai:nagasaki-u.repo.nii.ac.jp:00005660","sets":["29:30"]},"author_link":["24086","24082","24084","24087","24089","24083","24081","24078","24079","24088","24085","24090","24080"],"item_2_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2014-07-27","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"1318","bibliographicPageStart":"1314","bibliographicVolumeNumber":"20","bibliographic_titles":[{"bibliographic_title":"Medical Science Monitor"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background: High-dose (4.0 g/day) mesalazine is typically used for induction therapy, but its efficacy as maintenance therapy remains to be determined. We conducted a multicenter retrospective study to investigate the efficacy of continuous treatment with 4.0 g/day of mesalazine. Material/Methods: Japanese ulcerative colitis (UC) patients receiving acute induction therapy with 4.0 g/day mesalazine were enrolled and followed. Those who clinically improved or who achieved clinical remission were categorized into 2 sub-groups according to the median duration of treatment with 4.0 g/day of mesalazine. The clinical relapse frequency and the time to relapse were analyzed. Results: We enrolled 180 patients with active UC, and then 115 patients who clinically improved or who achieved clinical remission after treatment with 4.0 g/day mesalazine were categorized into 2 sub-groups according to the median of treatment duration: a short-term treatment group (?105 days, n=58) and a long-term treatment group (>105 days, n=57). Overall, 45 (39.1%) patients relapsed: 28 (48.3%) in the short-term treatment group and 17 (29.8%) in the long-term treatment group. This difference was statistically significant (p<0.05). The relapse- free rate in the long-term treatment group was significantly higher than that in the short-term treatment group (p<0.05). The mean time to relapse in the long-term treatment group was significantly longer than that in the short-term treatment group (425.6±243.8 days vs. 277.4±224.5 days; p<0.05). Conclusions: Long-term continuous treatment with high-dose mesalazine (4.0 g/day) may be more effective than short-term treatment for maintenance of remission in UC patients.","subitem_description_type":"Abstract"}]},"item_2_description_63":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"Medical Science Monitor, 20, pp.1314-1318; 2014","subitem_description_type":"Other"}]},"item_2_publisher_33":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"International Scientific Literature Inc."}]},"item_2_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.12659/MSM.890567","subitem_relation_type_select":"DOI"}}]},"item_2_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"c Med Sci Monit, 2014."},{"subitem_rights":"This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License"}]},"item_2_source_id_8":{"attribute_name":"EISSN","attribute_value_mlt":[{"subitem_source_identifier":"16433750","subitem_source_identifier_type":"ISSN"}]},"item_2_version_type_16":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Takeshima, Fuminao"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Matsumura, Masato"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Makiyama, Kazuya"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ohba, Kazuo"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Yamakawa, Masaki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nishiyama, Hitoshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Yamao, Takuji"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Akazawa, Yuko"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Yamaguchi, Naoyuki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ohnita, Ken"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ichikawa, Tatsuki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Isomoto, Hajime"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nakao, Kazuhiko"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-12-21"}],"displaytype":"detail","filename":"MSM20_1314.pdf","filesize":[{"value":"180.6 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"MSM20_1314.pdf","url":"https://nagasaki-u.repo.nii.ac.jp/record/5660/files/MSM20_1314.pdf"},"version_id":"726086ae-2db1-4b2c-b22d-27c6caa27d87"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Colitis, ulcerative - prevention & Control","subitem_subject_scheme":"Other"},{"subitem_subject":"Colitis, ulcerative - therapy","subitem_subject_scheme":"Other"},{"subitem_subject":"Mesalamine - administration & Dosage","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Efficacy of Long-Term 4.0 g/Day Mesalazine (Pentasa) for Maintenance Therapy in Ulcerative Colitis","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Efficacy of Long-Term 4.0 g/Day Mesalazine (Pentasa) for Maintenance Therapy in Ulcerative Colitis"}]},"item_type_id":"2","owner":"2","path":["30"],"pubdate":{"attribute_name":"公開日","attribute_value":"2014-10-03"},"publish_date":"2014-10-03","publish_status":"0","recid":"5660","relation_version_is_last":true,"title":["Efficacy of Long-Term 4.0 g/Day Mesalazine (Pentasa) for Maintenance Therapy in Ulcerative Colitis"],"weko_creator_id":"2","weko_shared_id":-1},"updated":"2023-05-16T03:01:23.626725+00:00"}